1 reports of this reaction
7.7% of all ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE reports
#7 most reported adverse reaction
HAEMORRHAGE is the #7 most commonly reported adverse reaction for ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE, manufactured by ARMY AND AIR FORCE EXCHANGE SERVICE. There are 1 FDA adverse event reports linking ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE to HAEMORRHAGE. This represents approximately 7.7% of all 13 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE who experience haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHAGE is moderately reported among ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE users, representing a notable but not dominant share of adverse events.
In addition to haemorrhage, the following adverse reactions have been reported for ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE:
The following drugs have also been linked to haemorrhage in FDA adverse event reports:
HAEMORRHAGE has been reported as an adverse event in 1 FDA reports for ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHAGE accounts for approximately 7.7% of all adverse event reports for ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE, making it a notable side effect.
If you experience haemorrhage while taking ACETAMINOPHEN, PAMABROM, PYRILAMINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.